X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
KER-050 (elritercept) is an engineered ligand trap comprised of a modified ligand-binding domain of the TGF-ß receptor known as activin receptor type IIA. It is being developed for Lower-Risk Myelodysplastic Syndromes.
Lead Product(s): Elritercept
Therapeutic Area: Oncology Product Name: KER-050
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2024
Details:
The net proceeds will be used to advance the development of KER-050, an investigational, modified activin receptor type IIA ligand, in two Phase 2 clinical trials, one in patients with myelodysplastic syndromes and one in patients with myelofibrosis.
Lead Product(s): Elritercept
Therapeutic Area: Hematology Product Name: KER-050
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co. LLC
Deal Size: $151.3 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 09, 2024
Details:
The net proceeds will be used to advance the development of KER-050, an investigational, modified activin receptor type IIA ligand, in two Phase 2 clinical trials, one in patients with myelodysplastic syndromes and one in patients with myelofibrosis.
Lead Product(s): Elritercept
Therapeutic Area: Hematology Product Name: KER-050
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co. LLC
Deal Size: $140.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 03, 2024
Details:
KER-065 is a novel ligand trap designed to bind to and inhibit TGF-ß ligands, including myostatin (GDF8) and activin A. It is being evaluated for the treatment of obesity.
Lead Product(s): KER-065
Therapeutic Area: Nutrition and Weight Loss Product Name: KER-065
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Details:
KER-047, is designed to selectively and potently inhibit ALK2, a TGF-β receptor. KER-047 is being developed for the treatment of functional iron deficiency which is a consequence of elevated ALK2 signaling, including the Company’s initial target, IRIDA.
Lead Product(s): KER-047
Therapeutic Area: Hematology Product Name: KER-047
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
KER-047, is designed to selectively and potently inhibit activin receptor-like kinase-2, a TGF-β superfamily receptor. KER-047 is being developed for the treatment of functional iron deficiency which is a consequence of elevated ALK2 signaling.
Lead Product(s): KER-047
Therapeutic Area: Hematology Product Name: KER-047
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
KER-012 is designed to bind to and inhibit the signaling of transforming growth factor-beta (“TGF-β”) ligands that suppress bone growth, including activin A and activin B.
Lead Product(s): KER-012
Therapeutic Area: Cardiology/Vascular Diseases Product Name: KER-012
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
Keros believes that KER-012 (“RKER-012”) has the potential to increase the signaling of bone morphogenic protein (“BMP”) pathways through this inhibition of activin A and activin B signaling, and consequently treat diseases.
Lead Product(s): RKER-012
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RKER-012
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2022
Details:
KER-050, is an engineered ligand trap comprised of a modified ligand-binding domain of the transforming growth factor-beta receptor known as activin receptor type IIA that is fused to the portion of the human antibody known as the Fc domain.
Lead Product(s): KER-050
Therapeutic Area: Oncology Product Name: KER-050
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2022
Details:
KER-012 is designed to bind to and inhibit the signaling of TGF-ß ligands that suppress bone growth, including activin A and activin B. KER-012 is being developed for the treatment of PAH and for the treatment of disorders associated with bone loss.
Lead Product(s): KER-012
Therapeutic Area: Hematology Product Name: KER-012
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
